Merck Sharp & Dohme 8-K Merck Announces 2006 Financial Results that Demonstrate Solid Revenue Growth

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2006

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	4Q `06			4Q `05			YTD 2006			YTD 2005
INTEREST INCOME	$	(199.7	)	$	(166.0	)	$	(764.3	)	$	(480.9	)
INTEREST EXPENSE		97.2			108.2			375.1			385.5
EXCHANGE (LOSSES) GAINS		(20.5	)		0.4			(25.0	)		(16.1	)
MINORITY INTERESTS		29.9			30.2			120.5			121.8
Other, net		16.0			(99.1	)		(89.0	)		(120.5	)
TOTAL	$	(77.1	)	$	(126.3	)	$	(382.7	)	$	(110.2	)

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	4Q `06		4Q `05		YTD 2006		YTD 2005
IVOMEC, HEARTGARD, other avermectins	$	106.7	$	117.3	$	468.7	$	467.5
FRONTLINE		154.3		144.0		886.9		757.7
Biologicals		165.1		149.0		600.7		533.2
Other Animal Health		63.0		57.0		238.4		229.1
TOTAL MERIAL SALES	$	489.1	$	467.3	$	2,194.7	$	1,987.5

Sanofi Pasteur-MSD	4Q `06		4Q `05		YTD 2006		YTD 2005
HEPATITIS VACCINES	$	16.6	$	15.0	$	70.9	$	81.0
VIRAL VACCINES		30.5		17.6		100.1		78.5
Other Vaccines		287.3		166.0		742.9		705.0
TOTAL SANOFI-MSD SALES	$	334.4	$	198.6	$	913.9	$	864.5

Merck / Schering-Plough Collaboration	4Q `06		4Q `05		YTD 2006		YTD 2005
VYTORIN (Worldwide)	$	552.9	$	354.9	$	1,955.3	$	1,028.3
ZETIA (Worldwide)		536.1		391.4		1,928.8		1,396.7
TOTAL	$	1,089.0	$	746.3	$	3,884.1	$	2,425.0

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2006

NET PRODUCT SALES DETAIL (millions of dollars)

	4Q `06 vs. 4Q `05
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		11	%		865		18	%		319		7	%		546
FOSAMAX		—			789		7	%		517		-11	%		272
SINGULAIR		17	%		960		21	%		691		9	%		268
ZOCOR		-65	%		379		-80	%		161		-15	%		218
Other Reported Products:
AGGRASTAT		-10	%		19		N/A			—		-10	%		19
ARCOXIA		33	%		74		N/A			—		33	%		74
CANCIDAS		-16	%		133		-46	%		49		25	%		84
COSOPT / TRUSOPT		7	%		179		9	%		80		6	%		100
CRIXIVAN / STOCRIN		-2	%		89		-41	%		7		4	%		82
EMEND		28	%		36		10	%		25		*			10
INVANZ		49	%		41		51	%		24		46	%		16
MAXALT		18	%		111		23	%		75		9	%		36
PRIMAXIN		-5	%		181		1	%		58		-8	%		124
PROPECIA		19	%		103		3	%		37		31	%		66
PROSCAR		-38	%		120		-75	%		25		2	%		95
TIMOPTIC / TIMOPTIC XE		-5	%		33		-5	%		2		-5	%		31
VASOTEC / VASERETIC		-10	%		136		N/A			—		-10	%		136
HEPATITIS VACCINES		39	%		67		50	%		57		—			11
VIRAL VACCINES (1)		*			482		*			453		*			30
OTHER VACCINES		20	%		134		26	%		118		-11	%		16

* 100% or over
N/A — Not Applicable

⁽¹⁾ Includes new vaccine sales: Gardasil $155m, ProQuad $89m, RotaTeq $69m, and Zostavax $27m.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	4Q '06		% CHG.			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES(2)	$	6,044		5	%		6		-2		1
U.S. ($ MM)		3,750		8	%		9		-1		N/A
Foreign ($ MM)		2,294		—			1		-4		3

⁽²⁾ Includes: Januvia $42m, Zolinza $1m.

Exhibit 99.2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
DECEMBER YEAR-TO-DATE
2006

NET PRODUCT SALES DETAIL (millions of dollars)

	DECEMBER YTD `06 vs. DECEMBER YTD `05
	TOTAL			TOTAL		U.S.			U.S.		Foreign			Foreign
PRODUCT	% CHG			$		% CHG			$		% CHG			$
COZAAR / HYZAAR		4	%		3,163		10	%		1,140		1	%		2,023
FOSAMAX		-2	%		3,134		8	%		1,983		-15	%		1,152
SINGULAIR		20	%		3,579		26	%		2,578		7	%		1,001
ZOCOR		-36	%		2,803		-40	%		1,887		-26	%		915
Other Reported Products:
AGGRASTAT		-2	%		86		N/A			—		-2	%		86
ARCOXIA		22	%		265		N/A			—		22	%		265
CANCIDAS		-7	%		530		-30	%		219		21	%		311
COSOPT / TRUSOPT		13	%		697		23	%		306		6	%		391
CRIXIVAN / STOCRIN		-6	%		327		-37	%		25		-2	%		302
EMEND		50	%		131		34	%		99		*			32
INVANZ		48	%		139		43	%		83		57	%		56
MAXALT		17	%		406		19	%		267		12	%		139
PRIMAXIN		-5	%		705		—			212		-6	%		493
PROPECIA		21	%		352		13	%		145		27	%		207
PROSCAR		-17	%		618		-34	%		244		1	%		375
TIMOPTIC / TIMOPTIC XE		-8	%		127		-14	%		9		-8	%		118
VASOTEC / VASERETIC		-12	%		547		N/A			—		-12	%		547
HEPATITIS VACCINES		28	%		248		34	%		202		5	%		47
VIRAL VACCINES (1)		*			1,257		*			1,161		57	%		96
OTHER VACCINES		14	%		354		22	%		294		-14	%		60

* 100% or over
N/A — Not Applicable

⁽¹⁾ Includes new vaccine sales: Gardasil $235m, ProQuad $235m, RotaTeq $163m, and Zostavax $39m.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	FY '06		% CHG.			VOL		PX		FX
TOTAL PHARMACEUTICAL SALES(2)	$	22,636		3	%		3		—		—
U.S. ($ MM)		13,777		8	%		6		2		N/A
Foreign ($ MM)		8,859		-4	%		-1		-3		-1

⁽²⁾ Includes: Januvia $43m, Zolinza $1m.